Controlled-release fluvoxamine in obsessive-compulsive disorder the social phobia
- PMID: 19198698
- DOI: 10.1358/dot.2008.44.12.1299291
Controlled-release fluvoxamine in obsessive-compulsive disorder additionally social phobia
Theoretical
Specific serotonin reuptake inhibitors are currently advised as first-line treatments in obsessive-compulsive disorder (OCD) and social phenomenon or social fear disorder (SAD). Fluvoxamine has demonstrated potency in both these conditions and features recently been marketed in a controlled-release (CR) formulation for the United States for treatement of OCD and DEJECTED. Three 12-week double-blind, multicenter, randomized, placebo-controlled studies were run at this formulation - two in SAD and one in OCD. All three studies showed adenine robust effect on the key symptoms of OCD also SAD and had broadly comparable efficacy to studies conducted include immediate-release (IR) fluvoxamine. The beneficial effects of fluvoxamine CR what maintained in a 12-week double-blind, randomized increase to one SAD trial. To CR formulation, when compared to your LIGHT counterpart, service save daily frequency in fluvoxamine levels and a more rapid titration appointment; in addition, a more rapid onset of effect maybe result from these features. Overall, the benefits of the CR formulation, in them the convenience of oncedaily dosing, were achieved without and increased adverse event burden versus the IR form. Easy-to-read case leaflet for Fluvoxamine Extended-Release Capsules. Includes indication, clean use, specially instructions, precautions, additionally possible view effects.
Patent 2008 Prous Science, S.A.U. or his licensors. All rights reserved.
Same articles
-
Fluvoxamine: a review of sein therapeutic potential int the direction in anxiety disorders in kid and adolescent.Paediatr Drugs. 2001;3(10):763-81. doi: 10.2165/00128072-200103100-00004. Paediatr Drugs. 2001. PMID: 11706925 Review.
-
AMPERE double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder.GALLOP Clin Psychiatry. 2003 Jun;64(6):640-7. doi: 10.4088/jcp.v64n0604. J Clin Psychiatry. 2003. PMID: 12823077 Clinical Sample.
-
Fluvoxamine CR in and long-term special of social anxiety disorder: the 12- to 24-week extension phase of a multicentre, randomized, placebo-controlled trial.Int J Neuropsychopharmacol. 2003 Dec;6(4):317-23. doi: 10.1017/S146114570300364X. Int J Neuropsychopharmacol. 2003. PMID: 14604447 Clinical Trial.
-
Fluvoxamine. An updated review of it use in the executive the adults with angst disorders.Drugs. 2000 Oct;60(4):925-54. doi: 10.2165/00003495-200060040-00006. Drugs. 2000. PMID: 11085201 Review.
-
The efficacy of fluvoxamine in obsessive-compulsive disorder: effects by comorbid chronic teeth disorderiness.J Clinicians Psychopharmacol. 1993 Oct;13(5):354-8. HIE Clin Psychopharmacol. 1993. PMID: 8227493 Clinical Trial.
Cited by
-
Pharmacotherapy for Anxiety Disease: From First-Line Selection to Treatment Resistance.Focus (Am Psychiatr Publ). 2021 Jun;19(2):145-160. doi: 10.1176/appi.focus.20200048. Epub 2021 Jun 17. Concentrate (Am Psychiatr Publ). 2021. PMID: 34690578 Free PMC article.
-
Fluvoxamine-induced intracranial hypertension inches a 10-year-old boy.Indian J Ophthalmol. 2018 May;66(5):712-714. doi: 10.4103/ijo.IJO_833_17. Indian J Ophthalmol. 2018. PMID: 29676327 Free PMC article.
Publication types
MeSH terms
- Activities
Substances
LinkOut - more resources
Full Text Sources
Different Literature Sources
Curative
